SKYE logo

SKYE
Skye Bioscience Inc

4,571
Mkt Cap
$28.59M
Volume
29.00
52W High
$5.75
52W Low
$0.5655
PE Ratio
-0.57
SKYE Fundamentals
Price
$0.8197
Prev Close
$0.8135
Open
$0.7737
50D MA
$0.7618
Beta
0.99
Avg. Volume
228,603.69
EPS (Annual)
-$1.41
P/B
3.20
Rev/Employee
$0.00
$4.27
Loading...
Loading...

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available
Poll

Earnings Recap

Reported GAAP EPS of -$0.32 down -14.29% YoY

Bullish

Skye Bioscience's nimacimab demonstrated incremental weight-loss benefits and a favorable tolerability profile, while the company progressed its CBeyond study and engaged Lilly Catalyze360 for Phase 2b trial design.

Bearish

Skye Bioscience's cash runway is limited, excluding future Phase 2b clinical and manufacturing costs, while net loss increased to $12.5M in Q1 2026, reflecting higher R&D expenses and operational risks.

Latest SKYE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.